Streamlining the Efficiency of PrEP Implementation

University of Washington746 enrolled

Overview

This is a pilot facility-based direct-to-pharmacy PrEP refill delivery to streamline care pathway in Kenyan public health HIV facilities implementing PrEP. Data on up to 500 PrEP users will be evaluated to understand delivery efficiency and in-depth interview with users and delivery key informants will be conducted to identify barriers and facilitators of implementation.

A prospective, pilot implementation evaluation of patient-centered differentiated care service. The core components of the multifaceted implementation strategy include: 1) 3-monthly refills, 2) direct-to-pharmacy refill visits, 3) HIV self-testing (HIVST) while waiting for refills, 4) Rapid risk assessment for ongoing risk, adherence, side effect, and acute HIV symptoms. Clinics will implement either: 1) current PrEP patient flow without any change or 2) a pilot differentiated pharmacy-based follow up PrEP care pathway. Clinics will implement only one delivery model thus eliminating risk for confusion in the clinic about delivery models and permitting a full-scale test of the system, since the efficiency in PrEP delivery is in part at the system level, above and beyond the individual client encounter. For this pilot project designed to primarily test delivery efficiency, feasibility and acceptability of direct-to-pharmacy care pathway at systems level using existing public health infrastructure, pilot and control clinics will be of comparable size selected to reflect the implementation nature of the design. The specific aims are: Aim 1: To evaluate whether a differentiated care model improves the efficiency of PrEP delivery while resulting in equivalent or better: 1) patient waiting time, 2) early PrEP continuation, and 3) adherence. Aim 2: Conduct mixed-methods study to understand patient and provider perception, experiences , feasibility and acceptability of a differentiated PrEP delivery model. Aim 3: Assess the efficiency, cost and cost-effectiveness of a facility-based differentiated PrEP care.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

746

Conditions

HIV Prevention HIV Preexposure Prophylaxis Implementation

Interventions

Direct-to-pharmacy oral PrEP refill visitsOTHER

Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: For HIV-negative participants: * Of legal age (≥18 years) * Able and willing to provide written informed consent for research component of the project (blood draw for adherence, brief surveys and in-depth qualitative interviews) * HIV uninfected based on negative HIV tests, per Kenya national guidelines * Currently or previously accessed PrEP at participating HIV clinic For Key delivery informants: * Able willing and able to provide consent in order to participate in the survey and qualitative interviews. * Works at any of the clinics implementing PrEP delivery. Key informants may include HIV testing service nurses, counselors, clinicians, social workers, or clinic managers. Exclusion Criteria: * Not meeting any of the inclusion criteria listed above.

Locations (1)

Partners in Health Research and Development

Thika, Kenya

Outcomes

Primary Outcomes

Patient wait time

Total waiting time at the clinic and contact time with providers measured by time and motion studies

Time frame: up to 6 months

PrEP continuation

Measured by return to clinic for PrEP refill

Time frame: up to 6 months

PrEP adherence

Measured objectively through tenofovir levels in dried blood spots at random subset of PrEP visits

Time frame: up to 6 months

Acceptability of direct-to-pharmacy PrEP care pathway

Assessed by the Acceptability of Intervention Psychometric Measure (AIM)

Time frame: up to 6 months

Acceptability of user HIV self-testing for PrEP care pathway

Assessed by the Acceptability of Intervention Psychometric Measure (AIM)

Time frame: up to 6 months

Feasibility of direct-to-pharmacy PrEP care pathway

Assessed by the Feasibility of Intervention Psychometric Measure (FIM)

Time frame: up to 6 months

Secondary Outcomes

Barriers to implementation of direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics

Evaluated through in-depth and key informants qualitative interviews

Time frame: up to 6 months

Facilitators to implementation of direct-to-pharmacy PrEP care pathway in Kenyan public health HIV clinics

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.